Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...
| Huvudupphovsmän: | , , , , , , , , |
|---|---|
| Materialtyp: | Conference item |
| Publicerad: |
2014
|
| _version_ | 1826267135502974976 |
|---|---|
| author | Sutherland, A Akhtar, M Zilvetti, M Brockmann, J Ruse, S Fuggle, S Sinha, S Harden, P Friend, P |
| author_facet | Sutherland, A Akhtar, M Zilvetti, M Brockmann, J Ruse, S Fuggle, S Sinha, S Harden, P Friend, P |
| author_sort | Sutherland, A |
| collection | OXFORD |
| description | mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6 months and stopping mycophenolate at 12 months. Here, we report the 6-year follow-up of 30 patients prospectively recruited to this single-arm pilot study and compare outcomes to a matched contemporaneous control group of 30 patients who received standard induction and calcineurin-inhibitor-based immunosuppression.Six-year patient and graft survival were 83% and 80%(alemtuzumab) versus 77% and 70% (control). Rejection rates in the first 6 months were similar in alemtuzumab (6.6%) and control groups (10%). A higher than expected incidence of rejection in the alemtuzumab group following cessation of mycophenolate at 1 year (17%) was mitigated in later patients by retaining low dose mycophenolate. Mean eGFR was higher in the alemtuzumab group at all time points but not significantly (p¼0.16). Tacrolimus levels in the first 6 months were significantly higher in the contemporaneous control group (p<0.001). Alemtuzumab induction with initial treatment with tacrolimus enables conversion to sirolimus without the side effects and incidence of acute rejection seen in earlier protocols. |
| first_indexed | 2024-03-06T20:49:34Z |
| format | Conference item |
| id | oxford-uuid:371df1e9-94a9-491d-a2aa-d2c5123d0a5f |
| institution | University of Oxford |
| last_indexed | 2024-03-06T20:49:34Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:371df1e9-94a9-491d-a2aa-d2c5123d0a5f2022-03-26T13:42:03ZAlemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:371df1e9-94a9-491d-a2aa-d2c5123d0a5fSymplectic Elements at Oxford2014Sutherland, AAkhtar, MZilvetti, MBrockmann, JRuse, SFuggle, SSinha, SHarden, PFriend, PmTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6 months and stopping mycophenolate at 12 months. Here, we report the 6-year follow-up of 30 patients prospectively recruited to this single-arm pilot study and compare outcomes to a matched contemporaneous control group of 30 patients who received standard induction and calcineurin-inhibitor-based immunosuppression.Six-year patient and graft survival were 83% and 80%(alemtuzumab) versus 77% and 70% (control). Rejection rates in the first 6 months were similar in alemtuzumab (6.6%) and control groups (10%). A higher than expected incidence of rejection in the alemtuzumab group following cessation of mycophenolate at 1 year (17%) was mitigated in later patients by retaining low dose mycophenolate. Mean eGFR was higher in the alemtuzumab group at all time points but not significantly (p¼0.16). Tacrolimus levels in the first 6 months were significantly higher in the contemporaneous control group (p<0.001). Alemtuzumab induction with initial treatment with tacrolimus enables conversion to sirolimus without the side effects and incidence of acute rejection seen in earlier protocols. |
| spellingShingle | Sutherland, A Akhtar, M Zilvetti, M Brockmann, J Ruse, S Fuggle, S Sinha, S Harden, P Friend, P Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title_full | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title_fullStr | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title_full_unstemmed | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title_short | Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study. |
| title_sort | alemtuzumab and sirolimus in renal transplantation six year results of a single arm prospective pilot study |
| work_keys_str_mv | AT sutherlanda alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT akhtarm alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT zilvettim alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT brockmannj alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT ruses alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT fuggles alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT sinhas alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT hardenp alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy AT friendp alemtuzumabandsirolimusinrenaltransplantationsixyearresultsofasinglearmprospectivepilotstudy |